BridgeMD
New treatment option for Crohn Disease
Official title A Study on the Impact of Online Positive Psychological Intervention on the Mental Health and Quality of Life of Crohn's Disease Patients
ClinicalTrials.gov ID: NCT06939712
What this study is testing
- What it's testing
- Crohn's disease (CD) is a chronic, nonspecific inflammatory disease that can affect the entire digestive tract. It is difficult to cure and often relapses, causing long-term suffering for patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients diagnosed with Crohn's disease according to the 2018 diagnostic criteria established by the Inflammatory Bowel Disease Group of the Chinese...
- Patients aged between 18 and 75 years;
- Patients with a score of 5-14 on the GAD-7 (indicative of mild to moderate anxiety) or a score of 5-14 on the PHQ-9 (indicative of mild to moderate...
- Patients who understand and agree to comply with the study requirements and have signed informed consent;
- Patients who are able to read and access the internet, either independently or with assistance from a family member, and are capable of using WeChat...
You likely can't join if
- Individuals with a history or current diagnosis of psychiatric illness or cognitive impairment, or those currently taking psychiatric medications...
- Individuals with concurrent other intestinal diseases or malignancies;
- Individuals with severe primary diseases of the cardiovascular, cerebrovascular, hepatic, or renal systems. Withdrawal Criteria:
- Patients lost to follow-up due to withdrawal or other reasons during the intervention period;
- Patients who develop severe complications or experience significant changes in their condition that prevent them from continuing the study.
See the full eligibility criteria
- Patients diagnosed with Crohn's disease according to the 2018 diagnostic criteria established by the Inflammatory Bowel Disease Group of the Chinese Medical Association's Gastroenterology Branch;
- Patients aged between 18 and 75 years;
- Patients with a score of 5-14 on the GAD-7 (indicative of mild to moderate anxiety) or a score of 5-14 on the PHQ-9 (indicative of mild to moderate depression);
- Patients who understand and agree to comply with the study requirements and have signed informed consent;
- Patients who are able to read and access the internet, either independently or with assistance from a family member, and are capable of using WeChat and mobile applications;
- Patients who are able to complete all course trainings and/or follow-up procedures.
- Individuals with a history or current diagnosis of psychiatric illness or cognitive impairment, or those currently taking psychiatric medications; Individuals working in the field of psychology, or those who have...
- Individuals with concurrent other intestinal diseases or malignancies;
- Individuals with severe primary diseases of the cardiovascular, cerebrovascular, hepatic, or renal systems. Withdrawal Criteria:
- Patients lost to follow-up due to withdrawal or other reasons during the intervention period;
- Patients who develop severe complications or experience significant changes in their condition that prevent them from continuing the study.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.